home > ict > spring 2014 > community care
International Clinical Trials

Community Care

ICT: Tell us a bit about Exostar and your position.

Richard Addi: Exostar empowers its customers to bring their products and services to market by creating cloudbased communities and applications where businesses and their partners can collaborate securely and productively through our connect-once Identity Hubs. We enforce the rules and privileges assigned by asset owners by verifying identities and controlling access, while providing a single sign-on user experience.

What are the most demanding information access requirements facing the life sciences industry?

The drug R&D process is changing to a collaborative model that increasingly relies on interactions between life sciences companies and external partners. Managing communities of partners requires seamless, immediate access to applications and information to optimise effi ciency. At the same time, intellectual property and sensitive data must be protected at all times, even as the breadth and depth of a community expands.

The open nature of the cloud prompted early concerns in the pharma industry – how much has this changed?

As cloud technology has matured and adoption has risen, concerns about the cloud have waned, but still exist. Public clouds, which are the most open, draw the most scrutiny. Private clouds are more secure, but stifle collaboration across enterprise boundaries. Hybrid ‘community’ clouds offer the best of both worlds – open enough for collaboration with partners, but closed enough to be secure.

The hybrid option allows companies to establish a community where the identities of all participants are clearly recognised, and the policies for information access and sharing are well defined by the participants and steadfastly enforced.

How successful at information sharing is life sciences compared to other industries you work with?

Life sciences and pharma companies are a bit behind other industries, but gaining ground fast as they transform their business model. We are leveraging our experience working with aerospace and defense firms to help accelerate the pace.

To date, there has been significant investment in the creation of portals and custom user interfaces to encourage collaboration and information sharing. But the focus is now shifting to the security side of the equation, with the implementation of more robust identity management solutions.

What are the specific benefits to clinical trials of cloud-based communities such as yours?

Successful clinical trials require identifying the right partners and building an environment that promotes easy, secure information exchange. Partners must be vetted to ensure they meet qualification standards, and their performance must be tracked to ensure they comply with governance rules and regulations.

We eliminate point-to-point connections between organisations, obtain and make available partner business data to members of the community, and work with members to define and enforce the rules of engagement. As a result, companies spend less on infrastructure and engage more quickly with the ideal resources to conduct a clinical trial.

You work in a fast-moving tech area – what do the next few years offer?

We see at least three significant trends for the next few years. Cloud, mobile, and social advances will propel even greater demand for collaboration – any time, any place. Big data technology will continue to evolve, but how information is collected and shared must be harnessed. Intrusions, breaches, and advanced persistent threats on systems, applications and information will become more numerous and sophisticated. All three trends point to the need for more robust, cloudbased identity and access management solutions that allow organisations and individuals in life sciences and other industries to collaborate with confidence across the community. And that is precisely where we will continue to invest.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

Richard Addi is President and Chief Executive Officer of Exostar. He previously held leadership positions at Rolls-Royce North America, Data Systems Solutions and Atlantic Research Corporation. Richard’s strategic management experience spans the life sciences, aerospace, defense and energy industries.
Print this page
Send to a friend
Privacy statement
News and Press Releases

Breakthrough in the global battle against polio: AJ Vaccines granted WHO prequalification for new polio vaccine

Despite ongoing concerted efforts to eradicate polio, it appears to be on the rise again with more cases registered in 2019 than 2018. Looking ahead, AJ Vaccines’ dose sparing technology provides a significant opportunity to expand supply, with the potential to deliver up to 100 million doses over the five-year period 2020-2024 to help meet the currently unmet global demand for inactivated polio vaccines.
More info >>

White Papers



Groth et al., 2007 and Jasencakova et al., 2010 Protein:protein-interactions (PPI) govern almost all important processes in living organisms. Thus, their rapid and accurate determination and investigation is a major challenge in life sciences. The extremely efficient and fast One-STrEP (Twin-Strep) system is suitable for the isolation of functional protein complexes and subsequent mass spectrometry analysis leads to the identification of protein complex components (Junttila et al., 2005) as it is shown in the following studies.
More info >>

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement